Jupiter Medical Center Adjusts Visitor Policy, Elective Procedures

Jupiter Medical Center today announced an update to its visitor policy to allow only one healthy visitor at a time, per patient.

Jupiter Medical Center advises visitors will be screened for potential exposure, travel history and upper respiratory tract symptoms. This new policy went into effect on Wednesday, March 18, and will remain in place until further notice.

Jupiter Medical Center is also in the process of rescheduling non-urgent, elective surgeries. This measure will minimize any potential spread among patients, as well as reduce the risk of exposure to team members and frontline providers. Jupiter Medical Center will continue to perform non-elective, urgent and emergency surgeries.

“In accordance with the Centers for Disease Control (CDC) and the American College of Surgeons recommendations, we are rescheduling elective surgeries to protect the health of our patients and caregivers at this time,” said Dr. Amit Rastogi, president and CEO of Jupiter Medical Center. “We recognize the impact on those patients whose procedures are being delayed and certainly look forward to amending our policy as events warrant.”

Jupiter Medical Center continues to conduct multidisciplinary training drills in preparation for screening, diagnosing, isolating and treating any potential cases of COVID-19, as well as ensuring the proper use of personal protective equipment in accordance with the Centers for Disease Control and Prevention recommended guidelines.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”